Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Aug 24, 2021 9:52pm
204 Views
Post# 33759339

Top Notch Team !!!

Top Notch Team !!!Bob had his chance to jump ship on the long halt ...but he didn't...he's got his list of credentials that show his worth in value that he brings to the table ...one negotiations ...another being his relationship with Salzman and fellow peers to make this transaction a success .... they knew the value of NO and the benefit it had to offer to fight off the various covid viruses...Bob went out and negotiated a deal...and the PP terms are pretty decent...the defined particulars show money coming in at different intervals...and just like the surprise halt ...anything can still happen...maybe after phase 1a & 1b a big pharma is already waiting..its in our best value to take the drug as far as we can on our own expense...much higher value in our return ....this could be their carreer ending success story ....alot of work was done getting us unhalted....a new name to help us move forward and financial support... during one of histories worst times to invest...someone at least gave us a chance ...gltal
<< Previous
Bullboard Posts
Next >>